You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexamethasone
Accession NumberDB01234  (APRD00674)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionAn anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]
Structure
Thumb
Synonyms
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
9alpha-Fluoro-16alpha-methylprednisolone
9α-Fluoro-16α-methylprednisolone
Decadron
Dexametasona
Dexamethasone
Dexamethasonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accufix II Dec Model 033-212implant.7 mgnil; refer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Decadron Phosphate Eye Ear Sol 0.1%liquid1 mgophthalmic; oticMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1960-12-311998-04-21Canada
Decadron Phosphate Inj 4mg/mlliquid4 mgintramuscular; intravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312001-08-01Canada
Decadron Tab 0.5mgtablet.5 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1958-12-312002-07-29Canada
Decadron Tab 4mgtablet4 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312003-08-08Canada
Dexamethasone Omega Unidosesolution10 mgintramuscular; intrasynovial; intravenousOmega Laboratories Ltd2013-05-08Not applicableCanada
Dexamethasone Sod Phos Inj 4mg/mlliquid4 mgintramuscular; intravenousTaro Pharmaceuticals Inc1989-12-312001-08-21Canada
Dexamethasone Sod Phosph Inj 10mg/ml USPliquid10 mgintramuscular; intrasynovial; intravenousSandoz Canada Incorporated1990-12-31Not applicableCanada
Dexamethasone Sodium Phosphate 0.1%drops.1 %ophthalmic; oticRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Dexamethasone Sodium Phosphate Inj USP 4mg/mlsolution4 mgintramuscular; intrasynovial; intravenousSandoz Canada Incorporated1986-12-31Not applicableCanada
Dexamethasone Sodium Phosphate Injection Sdzsolution10 mgintramuscular; intrasynovial; intravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection Sdzsolution4 mgintramuscular; intrasynovial; intravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection, USPliquid4 mgintra-articular; intramuscular; intravenousSterimax Inc1992-12-31Not applicableCanada
Dexamethasone Sodium Phosphate Injection, USPsolution4 mgintra-articular; intralesional; intramuscular; intravenous; soft tissue injectionMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection, USPsolution10 mgintramuscular; intravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Dexamethasone-omegaliquid4 mgintra-articular; intralesional; intramuscular; intravenous; soft tissue injectionOmega Laboratories Ltd1999-04-01Not applicableCanada
Dexamethasone-omegaliquid10 mgintramuscular; intravenousOmega Laboratories Ltd1999-06-30Not applicableCanada
Dexasone 0.5mgtablet0.5 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Dexasone 0.75mgtablet0.75 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Dexasone 4mgtablet4 mgoralValeant Canada Lp/valeant Canada s.e.c.1979-12-312016-07-08Canada
Diodex Solution 0.1%solution0.1 %ophthalmic; oticDioptic Pharmaceuticals Inc1994-12-31Not applicableCanada
Dom-dexamethasone Tablet 4mgtablet4 mgoralDominion Pharmacal1999-03-04Not applicableCanada
Encor Dec Model 033-159 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-443 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-448 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-757 Imp 0.5mg/impimplant0.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311996-09-10Canada
Encor Dec Model 033-856 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311996-09-10Canada
Hexadrol Phosphate Inj 10mg/mlliquid10 mgintramuscular; intravenousOrganon Teknika Canada Inc.1987-12-312001-09-18Canada
Hexadrol Phosphate Inj 4mg/mlliquid4 mgintramuscular; intravenousOrganon Teknika Canada Inc.1987-12-312001-09-18Canada
Maxidexsuspension1 mg/mLophthalmicAlcon Laboratories, Inc.1966-05-15Not applicableUs
Maxidex Ont 0.1%ointment0.1 %ophthalmicAlcon Canada Inc1966-12-31Not applicableCanada
Maxidex Sus 0.1%drops0.1 %ophthalmicAlcon Canada Inc1977-12-31Not applicableCanada
NeofordexTablet40 mgOral useLaboratoires Ctrs2016-03-16Not applicableEu
Ocudex Liq 0.1%liquid.1 %ophthalmic; topicalHerdt Et Charton Inc.1994-12-311999-09-17Canada
Odan-dexamethasonesolution0.1 %ophthalmic; oticOdan Laboratories Ltd1985-12-31Not applicableCanada
Ozurdeximplant.7 mg/1intravitrealAllergan, Inc.2009-09-01Not applicableUs
Ozurdeximplant0.7 mgintravitrealAllergan Inc2011-06-02Not applicableCanada
PHL-dexamethasoneliquid10 mgintramuscular; intravenousPharmel Inc2004-12-06Not applicableCanada
PHL-dexamethasonetablet0.75 mgoralPharmel Inc1998-02-17Not applicableCanada
PHL-dexamethasonetablet4 mgoralPharmel Inc1998-02-17Not applicableCanada
PHL-dexamethasoneelixir0.5 mgoralPharmel Inc2004-12-06Not applicableCanada
PHL-dexamethasonetablet0.5 mgoralPharmel Inc1998-02-17Not applicableCanada
PMS Dexamethasone Elixir 0.5mg/5mlliquid0.5 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS Dexamethasone Tab 0.5mg USPtablet0.5 mgoralPharmascience Inc1996-08-26Not applicableCanada
PMS Dexamethasone Tab 0.75mg USPtablet0.75 mgoralPharmascience Inc1996-09-05Not applicableCanada
PMS Dexamethasone Tab 4mgtablet4 mgoralPharmascience Inc1996-09-05Not applicableCanada
PMS-dexamethasonetablet2 mgoralPharmascience Inc2006-06-08Not applicableCanada
PMS-dexamethasone Sod Phosphate Dps 1mg/mldrops1 mgophthalmic; oticPharmascience Inc1989-12-31Not applicableCanada
PMS-dexamethasone Sod Phosphate Inj 10mg/mlliquid10 mgintramuscular; intravenousPharmascience Inc1990-12-31Not applicableCanada
PMS-dexamethasone Sod Phosphate Inj 4mg/mlsolution4 mgintra-articular; intramuscular; intravenousPharmascience Inc1989-12-31Not applicableCanada
Pro-dexamethasone - 4tablet4 mgoralPro Doc Limitee2008-07-04Not applicableCanada
R.O.-dexsonedrops.1 %ophthalmic; oticRichmond Pharmaceuticals Inc.1992-12-311997-08-11Canada
Ratio-dexamethasonetablet4 mgoralTeva Canada Limited1999-10-29Not applicableCanada
Ratio-dexamethasonetablet0.5 mgoralTeva Canada Limited1999-10-29Not applicableCanada
Ratio-dexamethasone Tablets, USPtablet0.75 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-10-292009-07-17Canada
Sandoz Dexamethasonedrops1 mgophthalmic; oticSandoz Canada Incorporated1990-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dexamethasonetablet4 mgoralApotex Inc2004-03-08Not applicableCanada
Apo-dexamethasonetablet0.5 mgoralApotex Inc2004-11-17Not applicableCanada
Baycadronelixir.5 mg/5mLoralWockhardt USA, LLC1983-07-27Not applicableUs
Dexamethasonetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Dexamethasonetablet1.5 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasonetablet4 mg/1oralH.J. Harkins Company, Inc.1983-04-28Not applicableUs
Dexamethasonetablet1.5 mg/1oralPhysicians Total Care, Inc.2005-06-13Not applicableUs
Dexamethasonetablet4 mg/1oralRoxane Laboratories, Inc1978-07-19Not applicableUs
Dexamethasonetablet4 mg/1oralbryant ranch prepack1978-07-19Not applicableUs
Dexamethasonetablet6 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonetablet4 mg/1oralAidarex Pharmaceuticals LLC1983-04-28Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1983-04-28Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2000-04-01Not applicableUs
Dexamethasonetablet.75 mg/1oralA S Medication Solutions Llc1983-04-28Not applicableUs
Dexamethasonetablet4 mg/1oralPd Rx Pharmaceuticals, Inc.1978-07-19Not applicableUs
Dexamethasonetablet2 mg/1oralRoxane Laboratories, Inc1982-08-26Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralRising Pharmaceuticals, Inc.2011-08-01Not applicableUs
Dexamethasonetablet1 mg/1oralRebel Distributors Corp1983-09-15Not applicableUs
Dexamethasonetablet1.5 mg/1oralPhysicians Total Care, Inc1996-06-21Not applicableUs
Dexamethasonetablet2 mg/1oralCardinal Health2011-06-29Not applicableUs
Dexamethasonetablet1 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonetablet1.5 mg/1oralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
Dexamethasonetablet6 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonetablet1.5 mg/1oralbryant ranch prepack2006-07-07Not applicableUs
Dexamethasonetablet.75 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Dexamethasonetablet4 mg/1oralSTAT Rx USA LLC1978-07-19Not applicableUs
Dexamethasonetablet4 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasonetablet.75 mg/1oralA S Medication Solutions Llc1975-06-03Not applicableUs
Dexamethasonetablet6 mg/1oralPhysicians Total Care, Inc2008-05-30Not applicableUs
Dexamethasonetablet4 mg/1oralPhysicians Total Care, Inc1994-01-19Not applicableUs
Dexamethasonesolution.5 mg/5mLoralRoxane Laboratories, Inc2007-11-01Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralQualitest Pharmaceuticals2011-05-11Not applicableUs
Dexamethasonetablet2 mg/1oralRebel Distributors Corp1982-08-26Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2009-04-01Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasonetablet.75 mg/1oralPd Rx Pharmaceuticals, Inc.1975-06-03Not applicableUs
Dexamethasonetablet.5 mg/1oralRoxane Laboratories, Inc1975-07-25Not applicableUs
Dexamethasonetablet4 mg/1oralDispensing Solutions, Inc.1978-07-19Not applicableUs
Dexamethasonetablet4 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Dexamethasonetablet.5 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasonetablet1.5 mg/1oralRoxane Laboratories, Inc2006-07-07Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasonetablet1 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonetablet.75 mg/1oralbryant ranch prepack1975-06-03Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralSTI Pharma LLC1976-09-21Not applicableUs
Dexamethasonetablet.75 mg/1oralRebel Distributors Corp1975-06-03Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2009-04-01Not applicableUs
Dexamethasonetablet6 mg/1oralPar Pharmaceutical Inc.1983-11-28Not applicableUs
Dexamethasonetablet2 mg/1oralPd Rx Pharmaceuticals, Inc.1982-08-26Not applicableUs
Dexamethasonetablet.75 mg/1oralPhysicians Total Care, Inc1996-05-10Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralCardinal Health1983-07-27Not applicableUs
Dexamethasonetablet.5 mg/1oralRoxane Laboratories, Inc1975-07-25Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasonetablet.75 mg/1oralRoxane Laboratories, Inc1975-06-03Not applicableUs
Dexamethasonetablet.75 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasonetablet.75 mg/1oralH.J. Harkins Company, Inc.1983-04-28Not applicableUs
Dexamethasonetablet2 mg/1oralPhysicians Total Care, Inc2005-06-21Not applicableUs
Dexamethasonetablet2 mg/1oralRoxane Laboratories, Inc1982-08-26Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2006-09-01Not applicableUs
Dexamethasonetablet4 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1978-07-19Not applicableUs
Dexamethasonetablet2 mg/1oralA S Medication Solutions Llc1982-08-26Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralSTI Pharma LLC1976-09-21Not applicableUs
Dexamethasonetablet4 mg/1oralRoxane Laboratories, Inc1978-07-19Not applicableUs
Dexamethasonetablet4 mg/1oralRebel Distributors Corp1978-07-19Not applicableUs
Dexamethasonetablet.5 mg/1oralPhysicians Total Care, Inc2009-01-28Not applicableUs
Dexamethasonetablet4 mg/1oralCardinal Health2011-06-29Not applicableUs
Dexamethasonetablet.75 mg/1oralRoxane Laboratories, Inc1975-06-03Not applicableUs
Dexamethasonetablet4 mg/1oralProficient Rx LP1978-07-19Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1983-04-28Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralMorton Grove Pharmaceuticals, Inc.1983-07-27Not applicableUs
Dexamethasonetablet1.5 mg/1oralRoxane Laboratories, Inc2006-07-07Not applicableUs
Dexamethasone Intensolsolution, concentrate1 mg/mLoralRoxane Laboratories, Inc1983-09-01Not applicableUs
Dexamethasone Intensolsolution, concentrate1 mg/mLoralCarilion Materials Management1983-09-01Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicStat Rx USA1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicSandoz Inc2004-07-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAmerican Regent, Inc.1990-09-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicA S Medication Solutions Llc1996-07-26Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicDispensing Solutions, Inc.2004-07-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintravenousREMEDYREPACK INC.2013-08-13Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intramuscular; intravenousGeneral Injectables and Vaccines, Inc2015-08-21Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousCardinal Health2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articularREMEDYREPACK INC.2015-07-17Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicRebel Distributors Corp1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicPhysicians Total Care, Inc.2005-06-20Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousCardinal Health1982-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2003-05-29Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2010-01-15Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousCardinal Health2003-05-29Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscularREMEDYREPACK INC.2013-08-13Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1982-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicRebel Distributors Corp1985-01-16Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAmerican Regent, Inc.1990-09-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicPhoenix Pharmaceutical, Inc.1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueGeneral Injectables and Vaccines, Inc2016-02-18Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicButler Animal Health Supply1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2005-04-05Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousCardinal Health2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueBD Rx Inc.2015-10-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscularREMEDYREPACK INC.2013-11-18Not applicableUs
Dexamethasone Sodium Phosphateinjection4 mg/5mLintra-articular; intralesional; intramuscular; intravenousGeneral Injectables & Vaccines, Inc.2011-07-18Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicMajor Pharmaceuticals1996-07-26Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicBausch & Lomb Incorporated1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAmerican Regent, Inc.1990-09-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueA S Medication Solutions Llc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousGENERAL INJECTABLES AND VACCINES, INC.2014-05-26Not applicableUs
Dexamethasone Sodium Phosphatesinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health1990-09-30Not applicableUs
Dexamethsonetablet4 mg/1oralNorthwind Pharmaceuticals, LLC2014-08-11Not applicableUs
Direct Rxtablet1.5 mg/1oralDIRECT RX2015-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DecadronSidus
Brand mixtures
NameLabellerIngredients
999 Itch ReliefChina Resources Sanjiu Medical & Pharmaceutical Co Ltd
CiprodexRebel Distributors Corp
Dioptrol OintmentDioptic Pharmaceuticals Inc
Dioptrol SuspensionDioptic Pharmaceuticals Inc
MaxitrolAlcon Laboratories, Inc.
Maxitrol OntAlcon Canada Inc
MethedexMajor Pharmaceuticals
Neo-poly-dexButler Animal Health Supply
Neodecadron Eye Ear Soln 0.1%Merck Frosst Canada & Cie, Merck Frosst Canada & Co.
Neomycin and Polymyxin B Sulfates and DexamethasonePaddock Laboratories, LLC
Neomycin Polymyxin B Sulfates and DexamethasoneMwi/Vet One
Neomycin Sulfate, Polymyxin B Sulfate and DexamethasoneSTAT RX LLC USA
NpdPhoenix Pharmaceutical, Inc.
Odan-trolOdan Laboratories Ltd
Sandoz OpticortSandoz Canada Incorporated
Sofracort Ear/eye OintmentRoussel Canada Inc.
Sofracort Sterile Ear/eye DropsSanofi Aventis Canada Inc
Sofracort Sterile Ear/eye OintmentHoechst Roussel Canada Inc.
TobradexAlcon Laboratories, Inc.
Tobradex Oph OintmentAlcon Canada Inc
Tobradex Oph SusAlcon Canada Inc
Tobradex STAlcon Laboratories, Inc.
Tobramycin and DexamethasoneRebel Distributors Corp
Salts
Name/CASStructureProperties
Dexamethasone acetate
Thumb
  • InChI Key: AKUJBENLRBOFTD-RPRRAYFGSA-N
  • Monoisotopic Mass: 434.210466929
  • Average Mass: 434.4977
DBSALT000383
Dexamethasone phosphate
ThumbNot applicableDBSALT001216
Dexamethasone sodium phosphate
Thumb
  • InChI Key: PLCQGRYPOISRTQ-FCJDYXGNSA-L
  • Monoisotopic Mass: 516.130121939
  • Average Mass: 516.4046
DBSALT000843
Categories
UNII7S5I7G3JQL
CAS number50-02-2
WeightAverage: 392.4611
Monoisotopic: 392.199902243
Chemical FormulaC22H29FO5
InChI KeyInChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationInjection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
PharmacodynamicsDexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.
Mechanism of actionDexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Related Articles
Absorption80-90%
Volume of distributionNot Available
Protein binding70%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Dexamethasone
6-beta-hydroxydexamethasoneDetails
Route of eliminationNot Available
Half life36-54 hours
ClearanceNot Available
ToxicityOral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Implantnil; refer (see dosage form).7 mg
Suspensionauricular (otic)
Suspensionotic
Suspension/ dropsauricular (otic)
Liquidophthalmic; otic1 mg
Tabletoral.5 mg
Elixiroral.5 mg/5mL
Solutionoral.5 mg/5mL
Tabletoral.5 mg/1
Tabletoral.75 mg/1
Tabletoral1 mg/1
Tabletoral1.5 mg/1
Tabletoral2 mg/1
Tabletoral4 mg/1
Tabletoral6 mg/1
Solution, concentrateoral1 mg/mL
Solutionintramuscular; intrasynovial; intravenous10 mg
Liquidintramuscular; intrasynovial; intravenous10 mg
Injectionintra-articular; intralesional; intramuscular; intravenous4 mg/5mL
Injectionintramuscular10 mg/mL
Injectionintramuscular; intravenous10 mg/mL
Injection, solutionintra-articular4 mg/mL
Injection, solutionintra-articular; intralesional; intramuscular; intravenous; soft tissue4 mg/mL
Injection, solutionintra-articular; intramuscular; intravenous4 mg/mL
Injection, solutionintramuscular4 mg/mL
Injection, solutionintramuscular; intravenous10 mg/mL
Injection, solutionintramuscular; intravenous4 mg/mL
Injection, solutionintravenous4 mg/mL
Solutionophthalmic1 mg/mL
Solution/ dropsophthalmic1 mg/mL
Solutionintramuscular; intrasynovial; intravenous4 mg
Liquidintra-articular; intramuscular; intravenous4 mg
Solutionintra-articular; intralesional; intramuscular; intravenous; soft tissue injection4 mg
Solutionintramuscular; intravenous10 mg
Liquidintra-articular; intralesional; intramuscular; intravenous; soft tissue injection4 mg
Solutionophthalmic; otic0.1 %
Ointmentophthalmic; topical
Implantrefer (see dosage form).5 mg
Implantrefer (see dosage form)0.5 mg
Liquidintramuscular; intravenous4 mg
Suspensionophthalmic1 mg/mL
Ointmentophthalmic0.1 %
Dropsophthalmic0.1 %
Ointmentophthalmic
Suspensionophthalmic
Solution/ dropsophthalmic
Liquidophthalmic; otic
TabletOral use40 mg
Liquidophthalmic; topical.1 %
Implantintravitreal.7 mg/1
Implantintravitreal0.7 mg
Elixiroral0.5 mg
Liquidoral0.5 mg
Tabletoral0.5 mg
Tabletoral0.75 mg
Tabletoral4 mg
Tabletoral2 mg
Liquidintramuscular; intravenous10 mg
Solutionintra-articular; intramuscular; intravenous4 mg
Dropsophthalmic; otic.1 %
Dropsophthalmic; otic1 mg
Solutionophthalmic; otic
Ointmentophthalmic; otic
Dropsophthalmic; otic
Dropstopical
Ointmenttopical
Suspension/ dropsophthalmic
Prices
Unit descriptionCostUnit
Ozurdex 0.7 mg implant1554.0USD implant
Maxidex 0.1% Suspension 15ml Bottle97.96USD bottle
Maxitrol 0.1-5-10000 Ointment 3.5 gm Tube87.3USD tube
Maxitrol 5-10000-0.1 Suspension 5ml Bottle75.88USD bottle
Maxidex 0.1% Suspension 5ml Bottle53.57USD bottle
Dexamethasone Sodium Phosphate 4 mg/ml Solution (1 Box = 25x1ml Vials)41.99USD box
Dexamethasone micronized powd41.31USD g
Dexamethasone powder21.27USD g
Dexamethasone Sodium Phosphate 0.1% Solution 5ml Bottle19.99USD bottle
Dexamethasone acetate powd15.12USD g
Dexamethasone sod ph powder14.24USD g
Dexamethasone Sodium Phosphate 4 mg/ml Solution 5ml Vial13.99USD vial
Dexamethasone Sodium Phosphate 10 mg/ml4.78USD ml
Dexamethasone Sodium Phosphate 4 mg/ml 1 Vial = 5ml4.0USD ml
Dexamethasone 0.1% eye drop3.43USD ml
Dexasol 0.1% eye drops3.38USD ml
Maxidex 0.1 % Ointment2.69USD g
Dexamethasone 10 mg/ml vial2.56USD ml
Maxidex 0.1% eye drops2.36USD ml
Dexamethasone Sodium Phosphate 4 mg/ml1.77USD ml
Maxidex 0.1 % Suspension1.73USD ml
Sandoz Dexamethasone Sod. Phosphate 0.1 % Solution1.38USD ml
Pms-Dexamethasone Sodium Phosp 10 mg/ml1.34USD ml
Dexamethasone 4 mg/ml vial1.04USD ml
Dexamethasone 6 mg tablet1.01USD tablet
Dexasone 4 mg Tablet0.86USD tablet
Apo-Dexamethasone 4 mg Tablet0.8USD tablet
Pms-Dexamethasone 4 mg Tablet0.8USD tablet
Ratio-Dexamethasone 4 mg Tablet0.8USD tablet
Dexamethasone 2 mg tablet0.68USD tablet
Dexamethasone 1 mg/1 ml soln0.65USD ml
Dexamethasone 4 mg tablet0.6USD tablet
Dexamethasone 1 mg tablet0.49USD tablet
Pms-Dexamethasone 0.75 mg Tablet0.47USD tablet
Pms-Dexamethasone 2 mg Tablet0.43USD tablet
Dexamethasone 0.5 mg/5ml Elixir0.4USD ml
Dexamethasone 0.75 mg tablet0.38USD tablet
Dexamethasone 1.5 mg tablet0.35USD tablet
Dexamethasone 0.5 mg tablet0.31USD tablet
Apo-Dexamethasone 0.5 mg Tablet0.21USD tablet
Pms-Dexamethasone 0.5 mg Tablet0.2USD tablet
Ratio-Dexamethasone 0.5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6284804 No2000-08-102020-08-10Us
US6359016 No2000-08-102020-08-10Us
US6726918 No2000-10-202020-10-20Us
US6899717 No2003-11-012023-11-01Us
US7033605 No2000-10-202020-10-20Us
US7767223 No2001-11-282021-11-28Us
US7795316 No2008-08-032028-08-03Us
US8034366 No2003-01-092023-01-09Us
US8034370 No2003-01-092023-01-09Us
US8043628 No2000-10-202020-10-20Us
US8063031 No2000-10-202020-10-20Us
US8088407 No2000-10-202020-10-20Us
US8101582 No2007-12-192027-12-19Us
US8450287 No2007-12-192027-12-19Us
US8506987 No2003-01-092023-01-09Us
US8846650 No2005-06-042025-06-04Us
US9012437 No2000-10-202020-10-20Us
US9149486 No2002-09-132022-09-13Us
US9192511 No2003-01-092023-01-09Us
US9283178 No2000-10-202020-10-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170-229Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation. Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.
water solubility89 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.83HANSCH,C ET AL. (1995)
logS-3.64ADME Research, USCD
Caco2 permeability-4.75ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation.
Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.

General ReferencesNot Available
External Links
ATC CodesR01AD03S02CA06S03CA01S01CB01S01BA01C05AA09H02AB02S02BA06D10AA03A01AC02D07AB19D07CB04D07XB05S03BA01S01CA01R01AD53
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (96 KB)
MSDSDownload (74.8 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with 1,10-Phenanthroline.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Dexamethasone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Dexamethasone.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Dexamethasone.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Dexamethasone.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Dexamethasone.
AcetaminophenThe serum concentration of Dexamethasone can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dexamethasone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dexamethasone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dexamethasone.
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Dexamethasone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Dexamethasone.
AfatinibThe serum concentration of Dexamethasone can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Dexamethasone.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Dexamethasone.
AlbendazoleThe serum concentration of Dexamethasone can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Dexamethasone.
AldesleukinDexamethasone may decrease the antineoplastic activities of Aldesleukin.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Dexamethasone.
AlectinibThe serum concentration of Dexamethasone can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Dexamethasone.
AlfentanilThe serum concentration of Dexamethasone can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Dexamethasone.
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Dexamethasone.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Dexamethasone.
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Dexamethasone.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Dexamethasone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dexamethasone.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Dexamethasone.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Dexamethasone.
Aluminum hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Dexamethasone can be decreased when combined with Aluminum phosphate.
AmantadineThe serum concentration of Dexamethasone can be increased when it is combined with Amantadine.
AmbenoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ambenonium.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Dexamethasone.
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Dexamethasone.
Aminohippuric acidThe serum concentration of Dexamethasone can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Dexamethasone.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dexamethasone.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dexamethasone.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Dexamethasone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Dexamethasone.
AmitriptylineThe serum concentration of Dexamethasone can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Dexamethasone.
AmlodipineThe serum concentration of Dexamethasone can be increased when it is combined with Amlodipine.
Amphotericin BDexamethasone may increase the hypokalemic activities of Amphotericin B.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Dexamethasone.
AmsacrineThe serum concentration of Dexamethasone can be increased when it is combined with Amsacrine.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Dexamethasone.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Dexamethasone.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Dexamethasone.
AprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Aprepitant.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Dexamethasone.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Dexamethasone.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Dexamethasone.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Dexamethasone.
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Dexamethasone.
AsparaginaseThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase.
Asparaginase Erwinia chrysanthemiThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Erwinia chrysanthemi.
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Dexamethasone.
AstemizoleThe serum concentration of Dexamethasone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Dexamethasone.
AtazanavirThe serum concentration of Dexamethasone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Dexamethasone.
AtenololThe serum concentration of Dexamethasone can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Dexamethasone can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Dexamethasone.
AtorvastatinThe serum concentration of Dexamethasone can be increased when it is combined with Atorvastatin.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Dexamethasone.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Dexamethasone.
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Dexamethasone.
AzelastineThe serum concentration of Dexamethasone can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Dexamethasone.
AzithromycinThe serum concentration of Dexamethasone can be increased when it is combined with Azithromycin.
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Dexamethasone.
BazedoxifeneThe serum concentration of Dexamethasone can be increased when it is combined with Bazedoxifene.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Dexamethasone.
BendroflumethiazideDexamethasone may increase the hypokalemic activities of Bendroflumethiazide.
BenzocaineThe serum concentration of Dexamethasone can be increased when it is combined with Benzocaine.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Dexamethasone.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Dexamethasone.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Dexamethasone.
BepridilThe serum concentration of Dexamethasone can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Dexamethasone.
BevacizumabBevacizumab may increase the cardiotoxic activities of Dexamethasone.
BexaroteneThe serum concentration of Dexamethasone can be decreased when it is combined with Bexarotene.
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Dexamethasone.
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Dexamethasone.
BiperidenThe serum concentration of Dexamethasone can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe bioavailability of Dexamethasone can be decreased when combined with Bismuth Subcitrate.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Dexamethasone.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Dexamethasone.
BoceprevirThe serum concentration of Dexamethasone can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Dexamethasone.
BortezomibThe metabolism of Dexamethasone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Dexamethasone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dexamethasone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dexamethasone.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Dexamethasone.
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Dexamethasone.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Dexamethasone.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Dexamethasone.
BromocriptineThe serum concentration of Dexamethasone can be increased when it is combined with Bromocriptine.
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Dexamethasone.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Dexamethasone.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Dexamethasone.
BumetanideDexamethasone may increase the hypokalemic activities of Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Dexamethasone.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Dexamethasone.
BuprenorphineThe serum concentration of Dexamethasone can be increased when it is combined with Buprenorphine.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Dexamethasone.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Dexamethasone.
BuspironeThe serum concentration of Dexamethasone can be increased when it is combined with Buspirone.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Dexamethasone.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Dexamethasone.
CabazitaxelThe serum concentration of Dexamethasone can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Dexamethasone.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Dexamethasone.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Dexamethasone.
CaffeineThe serum concentration of Dexamethasone can be increased when it is combined with Caffeine.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.
Calcium carbonateThe bioavailability of Dexamethasone can be decreased when combined with Calcium carbonate.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Dexamethasone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dexamethasone.
CanagliflozinThe serum concentration of Dexamethasone can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Dexamethasone can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Dexamethasone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Dexamethasone.
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Dexamethasone.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Dexamethasone.
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Dexamethasone.
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Dexamethasone.
CarvedilolThe serum concentration of Dexamethasone can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Dexamethasone.
CaspofunginThe serum concentration of Dexamethasone can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dexamethasone.
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Dexamethasone.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Dexamethasone.
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Dexamethasone.
CeritinibThe serum concentration of Dexamethasone can be increased when it is combined with Ceritinib.
CeritinibDexamethasone may increase the hyperglycemic activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Dexamethasone.
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Dexamethasone.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dexamethasone.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Dexamethasone.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Dexamethasone.
ChloroquineThe serum concentration of Dexamethasone can be increased when it is combined with Chloroquine.
ChlorothiazideDexamethasone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorotrianisene.
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Dexamethasone.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Dexamethasone.
ChlorpromazineThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dexamethasone.
ChlorpropamideThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorprothixene.
ChlorthalidoneDexamethasone may increase the hypokalemic activities of Chlorthalidone.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dexamethasone.
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Dexamethasone.
CholesterolThe serum concentration of Dexamethasone can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Dexamethasone can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Dexamethasone.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dexamethasone.
CilazaprilThe serum concentration of Dexamethasone can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Dexamethasone.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Dexamethasone.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Dexamethasone.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Dexamethasone.
CiprofloxacinThe serum concentration of Dexamethasone can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Dexamethasone.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Dexamethasone.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Dexamethasone.
CitalopramThe serum concentration of Dexamethasone can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Dexamethasone.
ClarithromycinThe serum concentration of Dexamethasone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Dexamethasone can be decreased when combined with Clemastine.
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Dexamethasone.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Dexamethasone.
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Dexamethasone.
ClofazimineThe serum concentration of Dexamethasone can be increased when it is combined with Clofazimine.
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Dexamethasone.
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Dexamethasone.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Dexamethasone.
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Dexamethasone.
ClomipramineThe serum concentration of Dexamethasone can be increased when it is combined with Clomipramine.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Dexamethasone.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Dexamethasone.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Dexamethasone.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Dexamethasone.
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Dexamethasone.
ClotrimazoleThe metabolism of Dexamethasone can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Dexamethasone.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Dexamethasone.
CobicistatThe serum concentration of Dexamethasone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Dexamethasone.
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Dexamethasone.
CodeineThe serum concentration of Codeine can be decreased when it is combined with Dexamethasone.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Dexamethasone.
ColchicineThe serum concentration of Dexamethasone can be increased when it is combined with Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Dexamethasone can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Dexamethasone can be increased when it is combined with Conivaptan.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Dexamethasone.
Conjugated Equine EstrogensThe serum concentration of Dexamethasone can be increased when it is combined with Conjugated Equine Estrogens.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Dexamethasone.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Dexamethasone.
CoumaphosThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Coumaphos.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Dexamethasone.
CrizotinibThe metabolism of Dexamethasone can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dexamethasone.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dexamethasone.
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Dexamethasone.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.
CyclosporineThe metabolism of Dexamethasone can be decreased when combined with Cyclosporine.
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Dexamethasone.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Dexamethasone.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Dexamethasone.
DaclatasvirThe serum concentration of Dexamethasone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Dexamethasone.
DactinomycinThe serum concentration of Dexamethasone can be increased when it is combined with Dactinomycin.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Dexamethasone.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Dexamethasone.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Dexamethasone.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Dexamethasone.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Dexamethasone.
DarunavirThe serum concentration of Dexamethasone can be increased when it is combined with Darunavir.
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Dexamethasone.
DasatinibThe serum concentration of Dexamethasone can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Dexamethasone.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Dexamethasone.
DecamethoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Decamethonium.
DeferasiroxThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Dexamethasone.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Dexamethasone.
DelavirdineThe metabolism of Dexamethasone can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Demecarium.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone.
DesipramineThe serum concentration of Dexamethasone can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dexamethasone.
DesloratadineThe serum concentration of Dexamethasone can be increased when it is combined with Desloratadine.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Dexamethasone can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dexamethasone.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Dexamethasone.
DichlorvosThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dichlorvos.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Dexamethasone.
DiclofenacThe serum concentration of Dexamethasone can be increased when it is combined with Diclofenac.
DienestrolThe serum concentration of Dexamethasone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Dexamethasone can be increased when it is combined with Diethylstilbestrol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dexamethasone.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Dexamethasone.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Dexamethasone.
DigoxinDigoxin may decrease the cardiotoxic activities of Dexamethasone.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Dexamethasone.
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dexamethasone.
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dexamethasone.
DihydroergotamineThe metabolism of Dexamethasone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDexamethasone may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Dexamethasone.
DiltiazemThe metabolism of Dexamethasone can be decreased when combined with Diltiazem.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Dexamethasone.
DipyridamoleThe serum concentration of Dexamethasone can be increased when it is combined with Dipyridamole.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Dexamethasone.
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Dexamethasone.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Dexamethasone.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone.
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Dexamethasone.
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Dexamethasone.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Dexamethasone.
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Dexamethasone.
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Dexamethasone.
DoxazosinThe serum concentration of Dexamethasone can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Dexamethasone.
DoxepinThe serum concentration of Dexamethasone can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Dexamethasone.
DoxycyclineThe metabolism of Dexamethasone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Dexamethasone.
DronabinolThe serum concentration of Dexamethasone can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Dexamethasone.
DronedaroneThe metabolism of Dexamethasone can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dexamethasone.
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Dexamethasone.
EchothiophateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Echothiophate.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Dexamethasone.
EdrophoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Edrophonium.
EfavirenzThe serum concentration of Dexamethasone can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Dexamethasone can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Dexamethasone.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Dexamethasone.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Dexamethasone.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dexamethasone.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Dexamethasone.
EnalaprilThe serum concentration of Dexamethasone can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Dexamethasone.
EnzalutamideThe serum concentration of Dexamethasone can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Dexamethasone.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Dexamethasone.
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Dexamethasone.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dexamethasone.
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Dexamethasone.
ErgonovineThe serum concentration of Dexamethasone can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Dexamethasone.
ErgotamineThe serum concentration of Dexamethasone can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Dexamethasone.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Dexamethasone.
ErythromycinThe metabolism of Dexamethasone can be decreased when combined with Erythromycin.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Dexamethasone.
Eslicarbazepine acetateThe serum concentration of Dexamethasone can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Dexamethasone.
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Dexamethasone.
EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Estradiol.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Dexamethasone.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Dexamethasone.
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Dexamethasone.
EstramustineThe serum concentration of Dexamethasone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Dexamethasone can be increased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Dexamethasone.
EstroneThe serum concentration of Dexamethasone can be increased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Dexamethasone.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dexamethasone.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Dexamethasone.
Etacrynic acidDexamethasone may increase the hypokalemic activities of Etacrynic acid.
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Dexamethasone.
Ethinyl EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Ethinyl Estradiol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dexamethasone.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Dexamethasone.
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Dexamethasone.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Dexamethasone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Dexamethasone.
EtoposideThe serum concentration of Dexamethasone can be increased when it is combined with Etoposide.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Dexamethasone.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Dexamethasone.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Dexamethasone.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Dexamethasone.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Dexamethasone.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Dexamethasone.
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Dexamethasone.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Dexamethasone.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Dexamethasone.
FelodipineThe serum concentration of Dexamethasone can be increased when it is combined with Felodipine.
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Dexamethasone.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Dexamethasone.
FentanylThe serum concentration of Dexamethasone can be increased when it is combined with Fentanyl.
FenthionThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fenthion.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Dexamethasone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Dexamethasone.
FexofenadineThe serum concentration of Dexamethasone can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Dexamethasone.
FidaxomicinThe serum concentration of Dexamethasone can be increased when it is combined with Fidaxomicin.
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Dexamethasone.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Dexamethasone.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Dexamethasone.
FluconazoleThe metabolism of Dexamethasone can be decreased when combined with Fluconazole.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Dexamethasone.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Dexamethasone.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Dexamethasone.
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Dexamethasone.
FluoxetineThe serum concentration of Dexamethasone can be increased when it is combined with Fluoxetine.
FluoxymesteroneDexamethasone may increase the fluid retaining activities of Fluoxymesterone.
FlupentixolThe serum concentration of Dexamethasone can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Dexamethasone can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Dexamethasone.
FlurazepamThe serum concentration of Dexamethasone can be increased when it is combined with Flurazepam.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Dexamethasone.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dexamethasone.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Dexamethasone.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Dexamethasone.
FluvoxamineThe metabolism of Dexamethasone can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Dexamethasone.
FosamprenavirThe metabolism of Dexamethasone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Dexamethasone.
FurosemideDexamethasone may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Fusidic Acid.
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Dexamethasone.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gallamine Triethiodide.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Dexamethasone.
GefitinibThe serum concentration of Dexamethasone can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Dexamethasone.
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Dexamethasone.
GenisteinThe serum concentration of Dexamethasone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ginkgo biloba.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dexamethasone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Dexamethasone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Dexamethasone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dexamethasone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Dexamethasone.
GlyburideThe serum concentration of Dexamethasone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Dexamethasone can be increased when it is combined with Glycerol.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Dexamethasone.
Gramicidin DThe serum concentration of Dexamethasone can be increased when it is combined with Gramicidin D.
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Dexamethasone.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Dexamethasone.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Dexamethasone.
GrepafloxacinThe serum concentration of Dexamethasone can be increased when it is combined with Grepafloxacin.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Dexamethasone.
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Dexamethasone.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Dexamethasone.
HaloperidolThe serum concentration of Dexamethasone can be increased when it is combined with Haloperidol.
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Dexamethasone.
HexestrolThe serum concentration of Dexamethasone can be increased when it is combined with Hexestrol.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Dexamethasone.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Dexamethasone.
Huperzine AThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.
HydrochlorothiazideDexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dexamethasone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Dexamethasone.
HydrocortisoneThe serum concentration of Dexamethasone can be increased when it is combined with Hydrocortisone.
HydroflumethiazideDexamethasone may increase the hypokalemic activities of Hydroflumethiazide.
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Dexamethasone.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dexamethasone.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Dexamethasone.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Dexamethasone.
IdelalisibThe serum concentration of Dexamethasone can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Dexamethasone.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dexamethasone resulting in a loss in efficacy.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Dexamethasone.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Dexamethasone.
ImatinibThe metabolism of Dexamethasone can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Dexamethasone.
ImipramineThe serum concentration of Dexamethasone can be increased when it is combined with Imipramine.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Dexamethasone.
IndacaterolIndacaterol may increase the hypokalemic activities of Dexamethasone.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Dexamethasone.
IndapamideDexamethasone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Dexamethasone.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Dexamethasone.
IndomethacinThe serum concentration of Dexamethasone can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dexamethasone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Dexamethasone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Dexamethasone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dexamethasone.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dexamethasone.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Dexamethasone.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Dexamethasone.
IsavuconazoniumThe metabolism of Dexamethasone can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Dexamethasone.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dexamethasone.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dexamethasone.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Dexamethasone.
IsradipineThe metabolism of Dexamethasone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Dexamethasone.
ItraconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Dexamethasone.
IvacaftorThe serum concentration of Dexamethasone can be increased when it is combined with Ivacaftor.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Dexamethasone.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Dexamethasone.
IvermectinThe serum concentration of Dexamethasone can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Dexamethasone.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Dexamethasone.
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Dexamethasone.
KetamineThe serum concentration of Dexamethasone can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Dexamethasone.
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Dexamethasone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Dexamethasone.
KetoconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Dexamethasone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Dexamethasone.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Dexamethasone.
LansoprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Dexamethasone.
LapatinibThe serum concentration of Dexamethasone can be increased when it is combined with Lapatinib.
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Dexamethasone.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Dexamethasone.
LeflunomideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Dexamethasone.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Dexamethasone.
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Dexamethasone.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Dexamethasone.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Dexamethasone.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Dexamethasone.
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Dexamethasone.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Dexamethasone.
LevofloxacinThe serum concentration of Dexamethasone can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dexamethasone.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Dexamethasone.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Dexamethasone.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Dexamethasone.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Dexamethasone.
LidocaineThe serum concentration of Dexamethasone can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Dexamethasone.
LiothyronineThe serum concentration of Dexamethasone can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Dexamethasone can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Dexamethasone.
LisinoprilThe serum concentration of Dexamethasone can be increased when it is combined with Lisinopril.
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Dexamethasone.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Dexamethasone.
LomitapideThe serum concentration of Dexamethasone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Dexamethasone.
LoperamideThe serum concentration of Dexamethasone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Dexamethasone.
LopinavirThe serum concentration of Dexamethasone can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Dexamethasone.
LoratadineThe serum concentration of Dexamethasone can be increased when it is combined with Loratadine.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Dexamethasone.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Dexamethasone.
LosartanThe serum concentration of Dexamethasone can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Dexamethasone.
LovastatinThe metabolism of Dexamethasone can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Dexamethasone can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Dexamethasone.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Dexamethasone.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Dexamethasone.
MagaldrateThe bioavailability of Dexamethasone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Malathion.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Dexamethasone.
MaprotilineThe serum concentration of Dexamethasone can be increased when it is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Dexamethasone.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Dexamethasone.
MebendazoleThe serum concentration of Dexamethasone can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dexamethasone.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Dexamethasone.
MefloquineThe serum concentration of Dexamethasone can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Dexamethasone can be increased when it is combined with Megestrol acetate.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Dexamethasone.
MemantineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Memantine.
MeprobamateThe serum concentration of Dexamethasone can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone.
MestranolThe serum concentration of Dexamethasone can be increased when it is combined with Mestranol.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Dexamethasone.
MethadoneThe serum concentration of Dexamethasone can be increased when it is combined with Methadone.
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Dexamethasone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Dexamethasone.
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Dexamethasone.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Dexamethasone.
MethyclothiazideDexamethasone may increase the hypokalemic activities of Methyclothiazide.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Dexamethasone.
MethyltestosteroneDexamethasone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneDexamethasone may increase the hypokalemic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Dexamethasone.
MetoprololThe serum concentration of Dexamethasone can be increased when it is combined with Metoprolol.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Dexamethasone.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Dexamethasone.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Dexamethasone.
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Dexamethasone.
MibefradilThe serum concentration of Dexamethasone can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Dexamethasone.
MiconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Dexamethasone.
MifepristoneThe therapeutic efficacy of Dexamethasone can be decreased when used in combination with Mifepristone.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Dexamethasone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dexamethasone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Dexamethasone.
MinaprineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Minaprine.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Dexamethasone.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Dexamethasone.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Dexamethasone.
MitomycinThe serum concentration of Dexamethasone can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Dexamethasone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Dexamethasone.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Dexamethasone.
ModafinilThe serum concentration of Dexamethasone can be decreased when it is combined with Modafinil.
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Dexamethasone.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Dexamethasone.
MorphineThe serum concentration of Dexamethasone can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dexamethasone.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Dexamethasone.
NafcillinThe serum concentration of Dexamethasone can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dexamethasone.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Dexamethasone.
NaltrexoneThe serum concentration of Dexamethasone can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Dexamethasone can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Dexamethasone.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Dexamethasone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Dexamethasone.
NeostigmineThe serum concentration of Dexamethasone can be increased when it is combined with Neostigmine.
NeostigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Neostigmine.
NetupitantThe serum concentration of Dexamethasone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Dexamethasone.
NevirapineThe metabolism of Dexamethasone can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Dexamethasone.
NicardipineThe serum concentration of Dexamethasone can be increased when it is combined with Nicardipine.
NicorandilThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nicorandil.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Dexamethasone.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Dexamethasone.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.
NilotinibThe metabolism of Dexamethasone can be decreased when combined with Nilotinib.
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Dexamethasone.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Dexamethasone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Dexamethasone.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Dexamethasone.
NisoldipineThe serum concentration of Dexamethasone can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Dexamethasone.
NitrazepamThe serum concentration of Dexamethasone can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Dexamethasone.
NitrendipineThe serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Dexamethasone.
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Dexamethasone.
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Dexamethasone.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Dexamethasone.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Dexamethasone.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Dexamethasone.
OlaparibThe metabolism of Dexamethasone can be decreased when combined with Olaparib.
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Dexamethasone.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Dexamethasone.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Dexamethasone.
OmeprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Omeprazole.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Dexamethasone.
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Dexamethasone.
OsimertinibThe serum concentration of Dexamethasone can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Dexamethasone.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Dexamethasone.
OuabainOuabain may decrease the cardiotoxic activities of Dexamethasone.
OxandroloneDexamethasone may increase the fluid retaining activities of Oxandrolone.
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Dexamethasone.
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Dexamethasone.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Dexamethasone.
OxymetholoneDexamethasone may increase the fluid retaining activities of Oxymetholone.
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Dexamethasone.
P-NitrophenolThe serum concentration of Dexamethasone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Dexamethasone.
PaclitaxelThe serum concentration of Dexamethasone can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Dexamethasone can be increased when it is combined with Palbociclib.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone.
Palmitic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Palmitic Acid.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Dexamethasone.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Dexamethasone.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Dexamethasone.
PantoprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Pantoprazole.
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Dexamethasone.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Dexamethasone.
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Dexamethasone.
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Dexamethasone.
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Dexamethasone.
ParoxetineThe serum concentration of Dexamethasone can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Dexamethasone.
PentobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Pentobarbital.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Dexamethasone.
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Dexamethasone.
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Dexamethasone.
PerindoprilThe serum concentration of Dexamethasone can be increased when it is combined with Perindopril.
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Dexamethasone.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Dexamethasone.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Dexamethasone.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Dexamethasone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Dexamethasone.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Dexamethasone.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Dexamethasone.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Dexamethasone.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Dexamethasone.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Dexamethasone.
PhysostigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Physostigmine.
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Dexamethasone.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Dexamethasone.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Dexamethasone.
PimozideThe serum concentration of Dexamethasone can be increased when it is combined with Pimozide.
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Dexamethasone.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Dexamethasone.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Dexamethasone.
PiretanideDexamethasone may increase the hypokalemic activities of Piretanide.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Dexamethasone.
Platelet Activating FactorThe serum concentration of Dexamethasone can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Dexamethasone.
Polyestradiol phosphateThe serum concentration of Dexamethasone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideDexamethasone may increase the hypokalemic activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Dexamethasone.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Dexamethasone.
PonatinibThe serum concentration of Dexamethasone can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Dexamethasone.
PosaconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Dexamethasone.
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Dexamethasone.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Dexamethasone.
PravastatinThe serum concentration of Dexamethasone can be increased when it is combined with Pravastatin.
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Dexamethasone.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Dexamethasone.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Dexamethasone.
PrazosinThe serum concentration of Dexamethasone can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Dexamethasone.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Dexamethasone.
PrednisoneThe serum concentration of Dexamethasone can be increased when it is combined with Prednisone.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Dexamethasone.
PrimidoneThe serum concentration of Dexamethasone can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Dexamethasone can be increased when it is combined with Probenecid.
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Dexamethasone.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Dexamethasone.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Dexamethasone.
PromazineThe serum concentration of Promazine can be decreased when it is combined with Dexamethasone.
PromethazineThe serum concentration of Dexamethasone can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Dexamethasone.
PropafenoneThe serum concentration of Dexamethasone can be increased when it is combined with Propafenone.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Dexamethasone.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Dexamethasone.
PropranololThe serum concentration of Dexamethasone can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Dexamethasone can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dexamethasone.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Dexamethasone.
PyridostigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pyridostigmine.
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Dexamethasone.
QuercetinThe serum concentration of Dexamethasone can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Dexamethasone.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Dexamethasone.
QuinacrineThe serum concentration of Dexamethasone can be increased when it is combined with Quinacrine.
QuinestrolThe serum concentration of Dexamethasone can be increased when it is combined with Quinestrol.
QuinethazoneDexamethasone may increase the hypokalemic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Dexamethasone.
QuinidineThe serum concentration of Dexamethasone can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Dexamethasone.
QuinineThe serum concentration of Dexamethasone can be increased when it is combined with Quinine.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Dexamethasone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rabies vaccine.
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Dexamethasone.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Dexamethasone.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Dexamethasone.
RanitidineThe serum concentration of Dexamethasone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Dexamethasone can be increased when it is combined with Ranolazine.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Dexamethasone.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Dexamethasone.
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Dexamethasone.
ReboxetineThe serum concentration of Dexamethasone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Dexamethasone.
RegorafenibThe serum concentration of Dexamethasone can be increased when it is combined with Regorafenib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Dexamethasone.
ReserpineThe serum concentration of Dexamethasone can be decreased when it is combined with Reserpine.
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Dexamethasone.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Dexamethasone.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Dexamethasone.
RifapentineThe serum concentration of Dexamethasone can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dexamethasone.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Dexamethasone.
RilpivirineThe serum concentration of Dexamethasone can be increased when it is combined with Rilpivirine.
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Dexamethasone.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Dexamethasone.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Dexamethasone.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Dexamethasone.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Dexamethasone.
RivastigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rivastigmine.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Dexamethasone.
RoflumilastRoflumilast may increase the immunosuppressive activities of Dexamethasone.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Dexamethasone.
RolapitantThe serum concentration of Dexamethasone can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone.
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Dexamethasone.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Dexamethasone.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dexamethasone.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Dexamethasone.
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Dexamethasone.
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Dexamethasone.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Dexamethasone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dexamethasone.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Dexamethasone.
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Dexamethasone.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Dexamethasone.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dexamethasone.
ScopolamineThe serum concentration of Dexamethasone can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Dexamethasone.
SelegilineThe serum concentration of Dexamethasone can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Dexamethasone.
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Dexamethasone.
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Dexamethasone.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Dexamethasone.
SertralineThe serum concentration of Dexamethasone can be increased when it is combined with Sertraline.
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Dexamethasone.
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Dexamethasone.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Dexamethasone.
SildenafilThe metabolism of Dexamethasone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dexamethasone.
SiltuximabThe serum concentration of Dexamethasone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Dexamethasone can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Dexamethasone.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Dexamethasone.
SimvastatinThe serum concentration of Dexamethasone can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Dexamethasone.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Dexamethasone.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Dexamethasone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Dexamethasone.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Dexamethasone.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Dexamethasone.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Dexamethasone.
SorafenibThe serum concentration of Dexamethasone can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Dexamethasone.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Dexamethasone.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Dexamethasone.
SpironolactoneThe serum concentration of Dexamethasone can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Dexamethasone can be decreased when it is combined with St. John's Wort.
StanozololDexamethasone may increase the fluid retaining activities of Stanozolol.
StaurosporineThe serum concentration of Dexamethasone can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Dexamethasone can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Dexamethasone can be decreased when it is combined with Streptozocin.
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone.
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Dexamethasone.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Dexamethasone.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Dexamethasone.
SulfinpyrazoneThe serum concentration of Dexamethasone can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Dexamethasone can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dexamethasone.
SumatriptanThe serum concentration of Dexamethasone can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Dexamethasone.
SunitinibThe serum concentration of Dexamethasone can be increased when it is combined with Sunitinib.
Synthetic Conjugated Estrogens, AThe serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dexamethasone.
Synthetic Conjugated Estrogens, BThe serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dexamethasone.
TacrineThe serum concentration of Dexamethasone can be increased when it is combined with Tacrine.
TacrineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Dexamethasone.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Dexamethasone.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Dexamethasone.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Dexamethasone.
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Dexamethasone.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Dexamethasone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Dexamethasone.
Taurocholic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Dexamethasone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Dexamethasone.
TelaprevirThe serum concentration of Dexamethasone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Dexamethasone.
TelithromycinThe serum concentration of Dexamethasone can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Dexamethasone can be increased when it is combined with Telmisartan.
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Dexamethasone.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Dexamethasone.
TemsirolimusThe serum concentration of Dexamethasone can be increased when it is combined with Temsirolimus.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Dexamethasone.
TerazosinThe serum concentration of Dexamethasone can be increased when it is combined with Terazosin.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Dexamethasone.
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Dexamethasone.
TerfenadineThe serum concentration of Dexamethasone can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Dexamethasone.
TestosteroneDexamethasone may increase the fluid retaining activities of Testosterone.
TestosteroneThe serum concentration of Dexamethasone can be increased when it is combined with Testosterone.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Dexamethasone.
ThalidomideDexamethasone may increase the dermatologic adverse activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dexamethasone.
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Dexamethasone.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Dexamethasone.
TiboloneThe serum concentration of Dexamethasone can be increased when it is combined with Tibolone.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.
TicagrelorThe serum concentration of Dexamethasone can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Dexamethasone.
TiclopidineThe metabolism of Dexamethasone can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Dexamethasone.
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Dexamethasone.
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Dexamethasone.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Dexamethasone.
TocilizumabThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.
TofacitinibDexamethasone may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dexamethasone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dexamethasone.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Dexamethasone.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Dexamethasone.
TolvaptanThe serum concentration of Dexamethasone can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dexamethasone.
TorasemideDexamethasone may increase the hypokalemic activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Dexamethasone.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Dexamethasone.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Dexamethasone.
TrastuzumabTrastuzumab may increase the neutropenic activities of Dexamethasone.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dexamethasone.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Dexamethasone.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Dexamethasone.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Dexamethasone.
TrichlorfonThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trichlorfon.
TrichlormethiazideDexamethasone may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Dexamethasone can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Dexamethasone can be increased when it is combined with Triflupromazine.
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Dexamethasone.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Dexamethasone.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Dexamethasone.
TrimipramineThe serum concentration of Dexamethasone can be increased when it is combined with Trimipramine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Dexamethasone.
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Dexamethasone.
TroleandomycinThe serum concentration of Dexamethasone can be increased when it is combined with Troleandomycin.
TubocurarineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tubocurarine.
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Dexamethasone.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Dexamethasone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Dexamethasone.
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Dexamethasone.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Dexamethasone.
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Dexamethasone.
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Dexamethasone.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Dexamethasone.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Dexamethasone.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Dexamethasone.
VenlafaxineThe metabolism of Dexamethasone can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Dexamethasone.
VerapamilThe metabolism of Dexamethasone can be decreased when combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Dexamethasone.
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Dexamethasone.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Dexamethasone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Dexamethasone.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Dexamethasone.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Dexamethasone.
VinorelbineThe serum concentration of Dexamethasone can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Dexamethasone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Dexamethasone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Dexamethasone.
VoriconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Dexamethasone.
WarfarinDexamethasone may increase the anticoagulant activities of Warfarin.
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Dexamethasone.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Dexamethasone.
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Dexamethasone.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Dexamethasone.
ZeranolThe serum concentration of Dexamethasone can be increased when it is combined with Zeranol.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dexamethasone.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Dexamethasone.
ZimelidineThe serum concentration of Dexamethasone can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Dexamethasone.
ZiprasidoneThe metabolism of Dexamethasone can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Dexamethasone.
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Dexamethasone.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Dexamethasone.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Dexamethasone.
Food Interactions
  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Warne JP, John CD, Christian HC, Morris JF, Flower RJ, Sugden D, Solito E, Gillies GE, Buckingham JC: Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1264-73. Epub 2006 Jul 11. [PubMed:16835395 ]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  3. Funato H, Kobayashi A, Watanabe Y: Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res. 2006 Oct 30;1117(1):125-34. Epub 2006 Sep 7. [PubMed:16956592 ]
  4. Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E: Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep. 2006 Jul-Aug;58(4):551-8. [PubMed:16963802 ]
  5. Wang D, Zhang H, Lang F, Yun CC: Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404. Epub 2006 Sep 13. [PubMed:16971495 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
stimulator
General Function:
Transcription factor binding
Specific Function:
Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency (By similarity).
Gene Name:
NR0B1
Uniprot ID:
P51843
Molecular Weight:
51717.185 Da
References
  1. Gummow BM, Scheys JO, Cancelli VR, Hammer GD: Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol Endocrinol. 2006 Nov;20(11):2711-23. Epub 2006 Jul 20. [PubMed:16857744 ]
  2. Yu CC, Li PH: In vivo inhibition of steroidogenic acute regulatory protein expression by dexamethasone parallels induction of the negative transcription factor DAX-1. Endocrine. 2006 Dec;30(3):313-23. [PubMed:17526944 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Structural molecule activity
Specific Function:
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing (PubMed:25664854). Functions ...
Gene Name:
ANXA1
Uniprot ID:
P04083
Molecular Weight:
38713.855 Da
References
  1. Morand EF, Hall P, Hutchinson P, Yang YH: Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006;2006(2):73835. [PubMed:16883066 ]
  2. John CD, Theogaraj E, Christian HC, Morris JF, Smith SF, Buckingham JC: Time-specific effects of perinatal glucocorticoid treatment on anterior pituitary morphology, annexin 1 expression and adrenocorticotrophic hormone secretion in the adult female rat. J Neuroendocrinol. 2006 Dec;18(12):949-59. [PubMed:17076770 ]
  3. Davies E, Omer S, Buckingham JC, Morris JF, Christian HC: Expression and externalization of annexin 1 in the adrenal gland: structure and function of the adrenal gland in annexin 1-null mutant mice. Endocrinology. 2007 Mar;148(3):1030-8. Epub 2006 Dec 7. [PubMed:17158208 ]
  4. Wang C, Wang J, Guo HF, Liu RY: Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett. 2007 Aug 15;111(2):103-10. Epub 2007 Jul 2. [PubMed:17644190 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Molecular Weight:
131116.3 Da
References
  1. Soderberg M, Raffalli-Mathieu F, Lang MA: Regulation of the murine inducible nitric oxide synthase gene by dexamethasone involves a heterogeneous nuclear ribonucleoprotein I (hnRNPI) dependent pathway. Mol Immunol. 2007 May;44(12):3204-10. Epub 2007 Mar 26. [PubMed:17379310 ]
  2. Huang H, Lavoie-Lamoureux A, Moran K, Lavoie JP: IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1147-54. [PubMed:17494951 ]
  3. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [PubMed:17503181 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V: Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 2001 Oct 5;167(1):37-46. [PubMed:11557128 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  3. Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG: Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ. 1995 Oct;6(10):1321-32. [PubMed:8845310 ]
  4. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  7. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
  8. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705. [PubMed:7560060 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R: Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999 Jan 15;442(2-3):208-14. [PubMed:9929003 ]
  2. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G: Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998 Mar 13;424(3):173-6. [PubMed:9539145 ]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000. [PubMed:20307139 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:01